Clene Nanomedicine develops catalytically-active nanocrystals that target cellular energy impairments in neurodegenerative diseases, aiming to restore and protect neuronal health. Their therapeutics address the critical need for effective treatments in a field with limited options for patients suffering from these conditions.
Funding
$7.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurodegenerative diseases like ALS, MS, and Parkinson's often involve impaired cellular energy production, leading to neuronal damage and loss of function. Current treatments offer limited efficacy in restoring neuronal health and slowing disease progression.
Solution
Clene Nanomedicine develops a pipeline of catalytically active nanocrystals designed to address cellular energy impairments in neurodegenerative diseases. Their lead therapeutic, CNM-Au8, is a gold nanocrystal suspension in clinical development as a disease-modifying treatment for ALS, MS, and Parkinson's disease. CNM-Au8 aims to restore and protect neuronal health by enhancing intracellular energy production and reducing oxidative stress. The company is also developing CNM-ZnAg, a zinc-silver ionic solution with antiviral and antimicrobial properties, CNM-AgZn17, a topical gel polymer suspension of silver and zinc ions for treating infectious diseases and accelerating wound healing, and CNM-PtAu7, a gold-platinum nanotherapeutic demonstrating broad-spectrum efficacy across a variety of tumor cell lines in initial in vitro research.
Target Audience
The primary target audience includes patients suffering from neurodegenerative diseases such as ALS, MS, and Parkinson's, as well as healthcare providers specializing in these conditions.
Features
- CNM-Au8: Gold nanocrystal suspension designed to enhance intracellular energy production and reduce oxidative stress.
- CNM-ZnAg: Proprietary zinc-silver ionic solution with demonstrated antiviral and antimicrobial properties.
- CNM-AgZn17: Topical gel polymer suspension of silver and zinc ions for treatment of infectious diseases and acceleration of wound healing.
- CNM-PtAu7: Gold-platinum nanotherapeutic demonstrating broad-spectrum efficacy across a variety of tumor cell lines in initial in vitro research.
- Pipeline includes treatments for Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson’s Disease (PD).